Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium
- 1 October 1995
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 238 (4) , 343-346
- https://doi.org/10.1111/j.1365-2796.1995.tb01208.x
Abstract
The International RET Mutation Consortium was first convened as part of the Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, in an attempt to analyse the relationship of RET mutation and disease phenotype in the autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes. Out of 361 families studied, 41% had MEN 2A, 17.7% MEN 2B, 6.4% FMTC and the remaining subjects were unclassified. RET mutations were detected in 87.3% of families overall. Over 93% of MEN 2B families had the RET 918 ATG → ACG mutation, while the most frequent mutation detected in MEN 2A families was cysteine codon 634 (87% of all mutations).Keywords
This publication has 6 references indexed in Scilit:
- Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.Proceedings of the National Academy of Sciences, 1994
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994
- Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTCNature Genetics, 1994
- A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaNature, 1994
- Mutations in the RET proto-oncogene are associated with MEN 2A and FMTCHuman Molecular Genetics, 1993
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature, 1993